Effects of thymosin in vitro in cancer patients and correlation with clinical course after thymosin immunotherapy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002272:Carcinoembryonic Antigen; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy; D005260:Female; D005353:Fibronectins; D006801:Humans; D007167:Immunotherapy; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D012907:Smoking; D013601:T-Lymphocytes; D013947:Thymosin / Q000627:therapeutic use*; D013951:Thymus Hormones / Q000627:therapeutic use*; D013997:Time Factors
D002272:Carcinoembryonic Antigen; D005353:Fibronectins; D013951:Thymus Hormones; D013947:Thymosin